OptiBiotix Health plc “US launch of cholesterol and blood pressure lowering product”

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning it plans for a US launch of LP(LDL) (R), its cholesterol and blood pressure lowering product, at Supply Side West in Las Vegas, on 27-28 September 2017. This follows the global manufacturing and supply agreement with Sacco S.r.l. announced on 22 August 2017.

The Supply Side West tradeshow brings together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries and is viewed as one of the world’s leading trade fairs for the food and drinks industry.

OptiBiotix will co-exhibit with Sacco and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain (LP(LDL) (R)) at the show, including:-

— CholBiome(R): a proprietary formulation containing LP(LDL) (R) to reduce cholesterol levels and blood pressure; and

   --      CardioBiome(R): a proprietary formulation containing LP(LDL) (R) to reduce a wide range of cardiovascular disease factors and improve long term heart health.

The US launch of LP(LDL) (R), CholBiome(R) and CardioBiome(R) at Supply Side West is the first of a number of commercial steps taken to supply LP(LDL) (R) to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations and presentations for distribution and sale into the US market.

The US is one of the largest and fastest-growing probiotic markets in the world, with supplements alone accounting for US$2.06bn sales, with a projected 55% growth to US$3.3bn by 2021. Discussions continue to progress with corporate partners for the manufacture and distribution of products containing LP(LDL) (R) in the European, Asian and other international markets.

Stephen O’Hara, CEO of OptiBiotix, commented: “OptiBiotix has made significant progress in raising industry awareness of its LP(LDL) (R) strain. This has created a high level of interest in commercialising products containing LP(LDL) (R) as a component in higher value branded products in markets globally. Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really